What happens between academic research and patients getting access to new drugs, and how we can improve it. I'm joined this week by my friend Ross Rheingans-Yoo, who has had an eclectic career, most recently in investment in pharmaceutical R&D. We chatted about what the lifecycle of drugs is, how trials are regulated by the FDA in the U.S. (and what the history is there), and how processes with many well-credentialed PhDs, lives hanging in the balance, and billions of dollars on the line are som...